Table III.
Group | Time of last challenge | Airway reactivity measurement | Histamine in BALF (nM/mL) | ||
---|---|---|---|---|---|
Re (cmH2O/mL/s) | Ri (cmH2O/mL/s) | Cldyn (mL/cmH2O) | |||
Negative control | D14 | 0.797 ± 0.106 | 0.571 ± 0.053 | 0.087 ± 0.004 | 2.35 ± 0.843 |
D21 | 0.863 ± 0.093 | 0.611 ± 0.060 | 0.085 ± 0.004 | 2.43 ± 0.806 | |
Positive control | D14 | 1.347 ± 0.150** | 1.028 ± 0.125** | 0.053 ± 0.007** | 18.4 ± 4.057** |
D21 | 1.380 ± 0.136** | 1.093 ± 0.107** | 0.051 ± 0.006** | 15.4 ± 4.473** | |
DTX/HP-SBE-β-CD | D14 | 0.836 ± 0.049 | 0.611 ± 0.034 | 0.086 ± 0.007 | 3.83 ± 1.357 |
D21 | 0.830 ± 0.035 | 0.666 ± 0.161 | 0.089 ± 0.003 | 3.15 ± 0.850 |
Data represent mean value ± SD, n = 4
*p < 0.05; **p < 0.01 (compared with negative control)
Re expiratory resistance, Ri inspiratory resistance, Cldyn dynamic pulmonary compliance, DTX docetaxel, HP-SBE-β-CD hydroxypropyl-sulfobutyl-β-cyclodextrin, BALF bronchoalveolar lavage fluid